STADA Arzneimittel AG’s $660 Million Investment in Takeda OTC Portfolio


Kirkland & Ellis advised STADA Arzneimittel AG on the US$660 million acquisition of a portfolio of over-the-counter and prescription pharmaceutical assets in Russia, Georgia and the CIS from Takeda Pharmaceutical Company Limited.

The portfolio include over-the-counter (OTC) and prescription pharmaceutical products exclusively in Russia, Georgia, and a number of countries from within the Commonwealth of Independent States, which form part of Takeda’s Growth & Emerging Markets Business Unit.

Takeda was advised by BofA Securities (financial advisor) and White & Case (legal advisor) in this transaction.

The team was led by transactional partners James Learner (Picture) and Jacob Traff; technology & IP transactions partner Emma Flett and tax partner Dulcie Daly; supported by associates Laura Lee Timko, John Patten, Ashley Eisenberg, Irfan Ahmed and Dragana Cvejic.

Involved fees earner: Irfan Ahmed – Kirkland & Ellis; Dragana Cvejic – Kirkland & Ellis; Dulcie Daly – Kirkland & Ellis; Ashley Eisenberg – Kirkland & Ellis; Emma Flett – Kirkland & Ellis; James Learner – Kirkland & Ellis; Laura Lee Timko – Kirkland & Ellis; John Patten – Kirkland & Ellis; Jacob Traff – Kirkland & Ellis;

Law Firms: Kirkland & Ellis;

Clients: STADA Arzneimittel AG;